Abstract: Compositions and methods are provided comprising choline acetyltransferase (ChAT) and PEGylated ChAT for treating hypertension.

Abstract: Methods are disclosed for treating a subject with metabolic syndrome, fatty liver disease, insulin resistance, inflammation or elevated body weight using hepatic ultrasound.

Abstract: Described herein are methods for treating a subject suffering from or at risk for a condition mediated by an inflammatory cytokine cascade, by electrically or mechanically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Abstract: A method of treating a disease or reducing the development of a symptom of a disease in a subject by administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to treat or reduce development of the disease or disease symptom.

Abstract: Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.

Abstract: Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Methods are disclosed for preventing systemic infection or controlling metastases or providing a vaccine adjuvant in a subject, the methods comprising stimulating one or more peripheral nerves innervating one or more lymph nodes of the subject.

Abstract: Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.

Abstract: A method of treating a disease or reducing the development of a symptom of a disease in a subject by administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to treat or reduce development of the disease or disease symptom.

Abstract: The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

Abstract: The subject matter of the present disclosure generally relates to techniques for neuromodulation of tissue that include applying energy (e.g., electromagnetic energy) into the target tissue to cause altered activity of a neuron in the tissue. In certain embodiments, the altered activity causes a change in one or molecules in the tissue or blood.

Abstract: Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.